A Pharmacokinetic and Pharmacodynamic Analysis of CPT‐11 and Its Active Metabolite SN‐38

Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata^1,2

1966 • 2,159 citations

Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11.

1991 • 855 citations

A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.

1992 • 438 citations

Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors.

1987 • 412 citations

Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.

1993 • 392 citations

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.

1992 • 363 citations

Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies.

1972 • 315 citations

Phase I and pharmacokinetic trial of weekly CPT-11.

1993 • 300 citations

Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse.

1990 • 292 citations

Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung Cancer

1991 • 275 citations

Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer.

1972 • 271 citations

Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880).

1970 • 246 citations

Irinotecan (CPT-11) High-Dose Escalation Using Intensive High-Dose Loperamide to Control Diarrhea

1994 • 242 citations

An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma.

1990 • 234 citations

Studies on the Antitumor Activity, Mechanism of Action, and Cell Cycle Effects of Camptothecin

1971 • 213 citations

Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.

1994 • 195 citations

Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: Characterization and mechanism of resistance

1991 • 168 citations

Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.

1993 • 161 citations

Treatment of malignant melanoma with camptothecin (NSC-100880).

1972 • 158 citations

CPT-11 Converting Enzyme from Rat Serum: Purification and Some Properties.

1991 • 139 citations

Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer.

1992 • 128 citations

Nonlinear pharmacokinetics of CPT-11 in rats.

1990 • 109 citations

Toxicity of camptothecin (NSC-100880).

1974 • 81 citations

Pharmacological Correlation between Total Drug Concentration and Lactones of CPT‐11 and SN‐38 in Patients Treated with CPT‐11

1995 • 54 citations

Lethal activity of camptothecin sodium on human lymphoma cells.

1974 • 54 citations

Phase I study of CPT-11 and etoposide in patients with refractory solid tumors.

1993 • 48 citations

Action of 7-ethylcamptothecin on tumor cells and its disposition in mice.

1987 • 18 citations

Cited By (0)

Loading...